EUCTR2017-004689-93-ES进行中（未招募）1 期
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide PlusDexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – dreaMM 6 - dreaMM 6
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •2. Male or female, 18 years or older (at the time consent is obtained).
- •3. Have confirmed diagnosis of Multiple Myeloma as defined by the International Myeloma Working Group (IMWG) (see Appendix 3, Section 13.3.1 of the Protocol).
- •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •5. Have undergone stem cell transplant (STC), or are considered transplant ineligible.
- •6. Have been previously treated with at least 1 prior line of MM therapy, and must have documented disease progression during or after their most recent therapy according to the IMWG criteria.
- •7. Must have at least ONE aspect of measurable disease, defined as one the following:
- •a. Urine M-protein excretion =200 mg/24h, or
- •b. Serum M-protein concentration =0.5 g/dL (=5.0 g/L), or
- •c. Serum free light chain (FLC) assay: involved FLC level =10 mg/dL
- •(=100 mg/L) and an abnormal serum free light chain ratio (<0.26 or >1.65).
- •8. Participants with a history of autologous stem cell transplant (SCT) are eligible for study participation provided the following eligibility criteria are met:
- •a. Autologous SCT was >100 days prior to study enrollment
- •b. No active bacterial, viral, or fungal infection(s) present
- •c. Participant meets the remainder of the eligibility criteria outlined in this protocol
- •9. All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE], Version 4.03, 2010) must be = Grade 1 at the time of enrollment, except for alopecia and Grade 2 neuropathy.
- •10. Adequate organ system functions as defined by laboratory assessments (please refer to table 8 in the protocol).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 58
排除标准
- •1. Systemic anti-myeloma therapy (including systemic steroids) within = 14 days, or plasmapheresis within 7 days prior to the first dose of study drug.
- •2. Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.
- •3. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs.
- •4. Prior allogenic stem cell transplant.
- •5. Evidence of active mucosal or internal bleeding.
- •6. Any major surgery within the last four weeks.
- •7. Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill criteria given in Table 8 in the Protocol
- •8. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant’s safety, obtaining informed consent or compliance to the study procedures.
- •9. Current active liver or biliary disease (with the exception of Gilbert’s syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease per investigator’s assessment).
- •10. Participants with previous or concurrent malignancies are allowed only if the second tumor is not contributing to the participant’s illness. The participant must not be receiving active therapy, other than hormonal therapy for this disease and the disease must be considered medically stable for at least 2 years.
- •11. Evidence of cardiovascular risk including any of the following:
- •a. QTc interval =470 msec. NOTE: the QTc is the QT interval corrected for heart rate according to Fridericia’s formula (QTcF).
- •b. Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block.
- •c. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening.
- •d. Class III or IV heart failure as defined by the New York Heart Association functional classification system (Appendix 6, Section 13.6 in the Protocol).
- •e. Uncontrolled hypertension.
- •12. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to GSK2857916, or any of the components of the study treatment.
- •13. Pregnant or lactating female.
- •14. Active infection requiring treatment.
- •15. Known HIV infection.
- •16. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at Screening or within 3 months prior to first dose of study treatment)
- •17. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment.
- •NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing
- •18. Current corneal disease except for mild punctuate keratopathy (Appendix 10, Section 13.10 in the Protocol). Note: Patients with mild punctate keratopathy are allowed.
- •Additional Exclusion Criteria for Participants Assigned to Treatment Arm A (GSK2857916 plus
研究者
相似试验
进行中（未招募）
1 期
study to evaluate the safety of the study drug, GSK2857916, at different doses and how well it works to treat people with multiple myeloma when taken together with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B).Relapsed / Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-004689-93-GBGlaxoSmithKline Research & Development Ltd152
进行中（未招募）
1 期
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)Pediatric Solid tumors and primary central nervous system (CNS) tumorsMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-505088-35-00F. Hoffmann-La Roche AG93
招募中
不适用
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid TumorsMaagdarmstelselneoplasmata benigneMetatstatic Solid TumorsSolid tumors10038666NL-OMON56048Astra Zeneca14
招募中
1 期
A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancerCTIS2022-502774-17-00AstraZeneca AB192
进行中（未招募）
1 期
A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancerAdvanced or Metastatic Non-small Cell Lung CarcinomaSolid TumorsEUCTR2021-000036-57-NLAstraZeneca AB81